The use of anti‐tumour necrosis factor‐α therapies for rheumatoid arthritis in Singapore
Identifieur interne : 001C44 ( Main/Exploration ); précédent : 001C43; suivant : 001C45The use of anti‐tumour necrosis factor‐α therapies for rheumatoid arthritis in Singapore
Auteurs : B. Y. H. Thong ; S. Vasoo [Singapour] ; E. T. KohSource :
- APLAR Journal of Rheumatology [ 0219-0494 ] ; 2006-08.
English descriptors
- Teeft :
- Adalimumab, Adverse effects, Aplar, Aplar journal, Arthritis, Arthritis rheum, Assay, Average dose, Azathioprine, Compassionate program, Congestive heart failure, Conventional dmards, Demyelinating disease, Disease duration, Dmard, Dmard combinations, Dmards, Etanercept, Immunosuppressive therapy, Major infection, Malignancy, Mantoux test, Median, Methotrexate, Necrosis factor, Radiographic, Remission, Rheumatic disease, Rheumatoid, Rheumatoid arthritis, Rheumatoid arthritis patients, Rheumatology, Singapore, Standard target dose, Tock seng hospital, Treatment duration.
Abstract
Anti‐tumour necrosis factor‐α (anti‐TNF‐α) agents are biologic disease‐modifying antirheumatic drugs (DMARDs) used in the treatment of moderate to severe rheumatoid arthritis (RA). We describe the demographic and therapeutic profiles of 22 patients who received anti‐TNF‐α therapy for RA in two hospitals in Singapore. The majority of patients were female, middle‐aged, full‐time working adults with limitation in their social or vocational activities. The mean RA disease duration was 101.4 ± 101.6 months (3.4–401.3). All received conventional DMARDs for a mean of almost 7 years before starting anti‐TNF‐α, with the majority having failed two or more DMARDs. The most commonly used anti‐TNF‐α therapies were infliximab (90.9%), etanercept (18.2%) and adalimumab (4.5%). Only one patient developed a major infection, while three developed minor infections requiring temporary cessation of anti‐TNF‐α therapy. There were no cases of malignancy, drug‐induced lupus, demyelinating disease or congestive heart failure during an average of 36.9 ± 21.9 months (3.9–63.0) from initiation of therapy.
Url:
DOI: 10.1111/j.1479-8077.2006.00191.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000C51
- to stream Istex, to step Curation: 000C51
- to stream Istex, to step Checkpoint: 000B12
- to stream Main, to step Merge: 001C56
- to stream Main, to step Curation: 001C44
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The use of anti‐tumour necrosis factor‐α therapies for rheumatoid arthritis in Singapore</title><author><name sortKey="Thong, B Y H" sort="Thong, B Y H" uniqKey="Thong B" first="B. Y. H." last="Thong">B. Y. H. Thong</name></author><author><name sortKey="Vasoo, S" sort="Vasoo, S" uniqKey="Vasoo S" first="S." last="Vasoo">S. Vasoo</name></author><author><name sortKey="Koh, E T" sort="Koh, E T" uniqKey="Koh E" first="E. T." last="Koh">E. T. Koh</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5883082B46DEA4DFD45074C1BBE5B91F4AF3673A</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1111/j.1479-8077.2006.00191.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-V36XV7BH-8/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000C51</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000C51</idno><idno type="wicri:Area/Istex/Curation">000C51</idno><idno type="wicri:Area/Istex/Checkpoint">000B12</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000B12</idno><idno type="wicri:doubleKey">0219-0494:2006:Thong B:the:use:of</idno><idno type="wicri:Area/Main/Merge">001C56</idno><idno type="wicri:Area/Main/Curation">001C44</idno><idno type="wicri:Area/Main/Exploration">001C44</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">The use of anti‐tumour necrosis factor‐α therapies for rheumatoid arthritis in Singapore</title><author><name sortKey="Thong, B Y H" sort="Thong, B Y H" uniqKey="Thong B" first="B. Y. H." last="Thong">B. Y. H. Thong</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author><author><name sortKey="Vasoo, S" sort="Vasoo, S" uniqKey="Vasoo S" first="S." last="Vasoo">S. Vasoo</name><affiliation wicri:level="1"><country xml:lang="fr">Singapour</country><wicri:regionArea>Division of Rheumatology, Department of Medicine, National University Hospital</wicri:regionArea><wicri:noRegion>National University Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Koh, E T" sort="Koh, E T" uniqKey="Koh E" first="E. T." last="Koh">E. T. Koh</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">APLAR Journal of Rheumatology</title><title level="j" type="alt">APLAR JOURNAL OF RHEUMATOLOGY</title><idno type="ISSN">0219-0494</idno><idno type="eISSN">1479-8077</idno><imprint><biblScope unit="vol">9</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="157">157</biblScope><biblScope unit="page" to="160">160</biblScope><biblScope unit="page-count">4</biblScope><publisher>Blackwell Publishing Asia</publisher><pubPlace>Melbourne, Australia</pubPlace><date type="published" when="2006-08">2006-08</date></imprint><idno type="ISSN">0219-0494</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0219-0494</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adalimumab</term><term>Adverse effects</term><term>Aplar</term><term>Aplar journal</term><term>Arthritis</term><term>Arthritis rheum</term><term>Assay</term><term>Average dose</term><term>Azathioprine</term><term>Compassionate program</term><term>Congestive heart failure</term><term>Conventional dmards</term><term>Demyelinating disease</term><term>Disease duration</term><term>Dmard</term><term>Dmard combinations</term><term>Dmards</term><term>Etanercept</term><term>Immunosuppressive therapy</term><term>Major infection</term><term>Malignancy</term><term>Mantoux test</term><term>Median</term><term>Methotrexate</term><term>Necrosis factor</term><term>Radiographic</term><term>Remission</term><term>Rheumatic disease</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatoid arthritis patients</term><term>Rheumatology</term><term>Singapore</term><term>Standard target dose</term><term>Tock seng hospital</term><term>Treatment duration</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Anti‐tumour necrosis factor‐α (anti‐TNF‐α) agents are biologic disease‐modifying antirheumatic drugs (DMARDs) used in the treatment of moderate to severe rheumatoid arthritis (RA). We describe the demographic and therapeutic profiles of 22 patients who received anti‐TNF‐α therapy for RA in two hospitals in Singapore. The majority of patients were female, middle‐aged, full‐time working adults with limitation in their social or vocational activities. The mean RA disease duration was 101.4 ± 101.6 months (3.4–401.3). All received conventional DMARDs for a mean of almost 7 years before starting anti‐TNF‐α, with the majority having failed two or more DMARDs. The most commonly used anti‐TNF‐α therapies were infliximab (90.9%), etanercept (18.2%) and adalimumab (4.5%). Only one patient developed a major infection, while three developed minor infections requiring temporary cessation of anti‐TNF‐α therapy. There were no cases of malignancy, drug‐induced lupus, demyelinating disease or congestive heart failure during an average of 36.9 ± 21.9 months (3.9–63.0) from initiation of therapy.</div></front></TEI><affiliations><list><country><li>Singapour</li></country></list><tree><noCountry><name sortKey="Koh, E T" sort="Koh, E T" uniqKey="Koh E" first="E. T." last="Koh">E. T. Koh</name><name sortKey="Thong, B Y H" sort="Thong, B Y H" uniqKey="Thong B" first="B. Y. H." last="Thong">B. Y. H. Thong</name></noCountry><country name="Singapour"><noRegion><name sortKey="Vasoo, S" sort="Vasoo, S" uniqKey="Vasoo S" first="S." last="Vasoo">S. Vasoo</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C44 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001C44 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:5883082B46DEA4DFD45074C1BBE5B91F4AF3673A
|texte= The use of anti‐tumour necrosis factor‐α therapies for rheumatoid arthritis in Singapore
}}
| This area was generated with Dilib version V0.6.33. |  |